Replimune (REPL) Research & Development (2017 - 2026)
Replimune (REPL) posted Research & Development of $52.3 million for Q1 2026, down 1.54% sequentially from $53.1 million in Q4 2025, and down 3.06% YoY from $54.0 million in Q1 2025.
Replimune (REPL) Research & Development (2017 - 2026) Analysis & Trends
Replimune has reported Research & Development for 10 years, with the latest figure at $52.3 million in Q1 2026.
- Quarterly Research & Development fell 3.06% year-over-year to $52.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $221.2 million (up 17.4% YoY) and the FY2026 annual result came in at $221.2 million, up 16.75% from the prior year.
- Research & Development fell to $52.3 million in Q1 2026 per REPL's latest filing, from $53.1 million in the prior quarter.
- Over five years, Research & Development peaked at $57.9 million in Q3 2025 and troughed at $21.7 million in Q1 2022.
- A 5-year average of $43.1 million and a median of $43.0 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2024: Research & Development soared 74.61% in 2023, then fell 11.51% in 2024.
- Over 5 years, Research & Development stood at $30.3 million in 2022, then surged by 41.59% to $42.8 million in 2023, then grew by 12.04% to $48.0 million in 2024, then rose by 10.7% to $53.1 million in 2025, then dropped by 1.54% to $52.3 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $52.3 million, $53.1 million, and $57.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Replimune | 1.24 Bn | 1.24 Bn | - | 52.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52.32 Mn |
| Dec 31, 2025 | 53.14 Mn |
| Sep 30, 2025 | 57.88 Mn |
| Jun 30, 2025 | 57.84 Mn |
| Mar 31, 2025 | 53.98 Mn |
| Dec 31, 2024 | 48.00 Mn |
| Sep 30, 2024 | 43.45 Mn |
| Jun 30, 2024 | 42.97 Mn |
| Mar 31, 2024 | 42.58 Mn |
| Dec 31, 2023 | 42.85 Mn |
| Sep 30, 2023 | 49.10 Mn |
| Jun 30, 2023 | 40.44 Mn |
| Mar 31, 2023 | 37.95 Mn |
| Dec 31, 2022 | 30.26 Mn |
| Sep 30, 2022 | 28.83 Mn |
| Jun 30, 2022 | 29.48 Mn |
| Mar 31, 2022 | 21.74 Mn |
| Dec 31, 2021 | 19.35 Mn |
| Sep 30, 2021 | 19.90 Mn |
| Jun 30, 2021 | 18.55 Mn |